Ristfor 유럽 연합 - 영어 - EMA (European Medicines Agency)

ristfor

merck sharp & dohme b.v. - sitagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus:ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (pparγ) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist.ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

ProQuad 유럽 연합 - 영어 - EMA (European Medicines Agency)

proquad

merck sharp & dohme b.v. - virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella - chickenpox; rubella; measles; mumps; immunization - vaccines - proquad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. proquad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.,

Parareg 유럽 연합 - 영어 - EMA (European Medicines Agency)

parareg

dompé biotec s.p.a. - cinacalcet - hypercalcemia; parathyroid neoplasms; hyperparathyroidism - calcium homeostasis - treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy.mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate (see section 5.1).reduction of hypercalcaemia in patients with:-parathyroid carcinoma.- primary hpt for whom parathyroidectomy would be indicated on the basis of serum calciumlevels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Stocrin 유럽 연합 - 영어 - EMA (European Medicines Agency)

stocrin

merck sharp & dohme b.v. - efavirenz - hiv infections - antivirals for systemic use - stocrin is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (hiv-1)-infected adults, adolescents and children three years of age and older.stocrin has not been adequately studied in patients with advanced hiv disease, namely in patients with cd4 counts < 50 cells/mm3, or after failure of protease-inhibitor (pi)-containing regimens. although cross-resistance of efavirenz with pis has not been documented, there are at present insufficient data on the efficacy of subsequent use of pi-based combination therapy after failure of regimens containing stocrin.

Tesavel 유럽 연합 - 영어 - EMA (European Medicines Agency)

tesavel

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus, tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a pparγ agonist (i.e. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (pparγ) agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.